Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection. Our technology has the potential to simplify the whole cycle of cancer management through utilizing a novel, non-invasive procedure called liquid biopsy.
We provide a competitive and differentiated proposal with superior predictive power potential by identifying panels of circulating wild-type and mutant proteins in blood at the point-of-care. Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies.
As a spin-off from Tokyo Institute of Technology, we are currently collaborating with the University of Cambridge to develop an integrated prototype device.
As a spin-off from Tokyo Institute of Technology, we are currently collaborating with the University of Cambridge to develop an integrated prototype device.
Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection. Our technology has the potential to simplify the whole cycle of cancer management through utilizing a novel, non-invasive procedure called liquid biopsy.
Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection. Our technology has the potential to simplify the whole cycle of cancer management through utilizing a novel, non-invasive procedure called liquid biopsy.
We provide a competitive and differentiated proposal with superior predictive power potential by identifying panels of circulating wild-type and mutant proteins in blood at the point-of-care.
Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies. As a spin-off from Tokyo Institute of Technology, we are currently collaborating with the University of Cambridge to develop an integrated prototype device.
Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies. As a spin-off from Tokyo Institute of Technology, we are currently collaborating with the University of Cambridge to develop an integrated prototype device.
We provide a competitive and differentiated proposal with superior predictive power potential by identifying panels of circulating wild-type and mutant proteins in blood at the point-of-care.
Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies. As a spin-off from Tokyo Institute of Technology, we are currently collaborating with the University of Cambridge to develop an integrated prototype device.
Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies. As a spin-off from Tokyo Institute of Technology, we are currently collaborating with the University of Cambridge to develop an integrated prototype device.
